Earnings ·
Nyxoah raises Q3 revenue to €9.2M but cuts full-year guidance to €33-€35M
NYXHNyxoah SA
Nyxoah reported preliminary third-quarter global net revenue of approximately €9.2 million, reflecting 19% sequential growth driven by a 29% increase in U.S. sales to €6.7 million. The company also announced that its ACCCESS pivotal study met efficacy endpoints for Complete Concentric Collapse patients and submitted a PMA supplement to the FDA to expand Genio’s indication. However, Nyxoah lowered its full-year 2026 revenue guidance to €33-€35 million from the previous range of €36-€40 million due to slower-than-expected commercial ramp-up in the U.S. market. The company ended the quarter with approximately €77.0 million in cash and financial assets.